medigraphic.com

2017, Number 3

<< Back Next >>

Rev Hosp Jua Mex 2017; 84 (3)

Helicobacter pylori eradication frequency of response with the first-line treatment Experience in the Department of Gastroenterology of the Juarez Hospital of Mexico

Largacha-Barreiro ML, Juárez-Valdés EI, Ángeles-Labra AR, Zamarripa-Dorsey F

Language: Spanish
References: 28
Page: 131-136
PDF size: 173.82 Kb.


ABSTRACT

Introduction: Current evidence shows that Helicobacter pilory (Hp) eradication rates obtained with treatment based on a proton pump inhibitor (PPI), clarithromycin and amoxicillin have decreased to 70-85%; due to increasing resistance to clarithromycin. Objective: To evaluate the response to eradication treatment for Hp. Of the first line in the patients treated in the external consultation of Gastroenterology of the Hospital Juárez de México. Material and methods: Retrospective, descriptive study with records of patients undergoing treatment for Hp eradication. A base of amoxicillin 1 gram w/12 hours; claritomycin 500 mg with 12 hours and pantoprazol 40 mg with 12 hours for 14 days; From January 2011 to June 2015. Results: We included 216 cases with histopathological diagnosis of Hp, mean age 40 years, 78% of females (n = 169), post-treatment, to evaluate eradication of Hp 80% breath test (n = 173) of the patients and the rest 20% (n = 43) antigen in feces; (n = 22), respectively, 16% (n = 34) of patients required second-line treatment, of which 67.64 (n = 23) were negative and the rest were submitted to third line handling. Conclusions: Resistance to first-line treatment is lower than that reported in the United States of North America.


REFERENCES

  1. Hunt RH, Xiao SD, Megraud FF, Leon-Barrúa R, Bazzoli F, van der Merwe S, et al. Guías prácticas de la Organización Mundial de Gastroenterología: Helicobacter pylori en los países en desarrollo. Gastroenterol Latinoam 2010; 21(2):165-81.

  2. Guía clínica AUGE. Tratamiento de erradicación de Helicobacter pylori en el paciente con úlcera péptica Ministerio De Salud. Guía Clínica. Santiago: MINSAL; 2013. Disponible en: http://web.minsal.cl/portal/url/item/db8329e1effc9a22e040010165015626.pdf3.

  3. Noble-Lugo A. Novedades en Helicobacter pylori. Rev Gastroenterol Mex 2011; 76 (Supl.1): 29-32.

  4. Mégraud F. Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes 2013; 4(6): 541-8.

  5. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59(8): 1143-53.

  6. Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GL, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; (12): CD008337.

  7. Li BZ, Threapleton DE, Wang JY, Xu JM, Yuan JQ, Zhang C et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ 2015; 351: h4052.

  8. Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016; 43(4): 514-33.

  9. Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Yamade M, et al. Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. Expert Opin Pharmacother 2007; 8(16): 2701-17.

  10. Lee JW, Kim N, Nam RH, Park JH, Kim JM, Jung HC, et al. Mutations of Helicobacter pylori in fluoroquinolone resistance and the effect of point mutation of gyrA on the second line eradication therapy in Korea. Helicobacter 2011; 16(4): 301-10.

  11. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F et al. Management of Helicobacter pylori infection--the Maastricht IV/florence consensus report. Gut 2012; 61(5): 646-64.

  12. Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378(9790): 507-14.

  13. De Francescoa V, Bellesiaa A, Ridolab L, Mantac R, Zullod A. First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines. Ann Gastroenterol 2017; 30(4): 373-9.

  14. Huang CC, Tsai KW, Tsai TJ, Hsu PI. Update on the first-line treatment for Helicobacter pylori infection - a continuing challenge from an old enemy. Biomark Res 2017; 11: 5-23.

  15. Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone CA, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Sys Rev 2016; (6): CD009034.

  16. Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102(8): 1808-25. Epub 2007 Jun 29.

  17. Gisbert JP, Calvet X, Bermejo F, Boixeda D, Bory F, Bujanda L, et al. III Conferencia Española de Consenso sobre la infección por Helicobacter pylori. Gastroenterol Hepatol 2013; 36(5): 340-74.

  18. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine. Clin Gastroenterol Hepatol 2014; 12(2): 177-86.

  19. Rodríguez-García JL, Carmona-Sánchez R. Dispepsia funcional y dispepsia asociada a infección por Helicobacter pylori: ¿son entidades con características clínicas diferentes? Rev Gastroenterol Mex 2016; 81(3): 126-33.

  20. Porras C, Nodora J, Sexton R, Ferreccio C, Jimenez S, Dominguez RL et al. Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes Control 2013; 24(2): 209-15.

  21. Carmona-Sánchez R. ¿Cuál es el papel de la infección por Helicobacter pylori en la dispepsia en el 2015? In trastornos funcionales digestivos y enfermedades gastroduodenales. Clave Editorial México 2015; 66-74.

  22. Zullo A, Hassan C, De Francesco V, Repici A, Manta R, Tomao S, et al. Helicobacter pylori and functional dyspepsia: an unsolved issue? World J Gastroenterol 2014; 20(27): 8957-63.

  23. Everhart JE. Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clin North Am 2000; 29(3): 559-78.

  24. Peterson WL, Fendrick AM, Cave DR, Peura DA, Garabedian-Ruffalo SM, Laine L. Helicobacter pylori-related disease: Guidelines for testing and treatment. Arch Intern Med 2000; 160: 1285-91.

  25. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998; 93(12): 2330-38.

  26. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfetheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001; 15(12): 1949-58.

  27. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004; 99(9): 1833-55.

  28. Sharma VK, Sahai AV, Corder FA, Howden CW. Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage. Aliment Pharmacol




2020     |     www.medigraphic.com